188 related articles for article (PubMed ID: 17365824)
21. Alterations of the K-ras and p53 genes in Tamoxifen-associated endometrial carcinoma.
Fujiwara K; Enomoto T; Fujita M; Kanda T; Fujii S; Ito K; Wakasa K; Ishiko O; Ueda M; Yamaguchi S; Kimura T; Umesaki N
Oncol Rep; 2008 May; 19(5):1293-8. PubMed ID: 18425390
[TBL] [Abstract][Full Text] [Related]
22. Cell signaling in endometrial carcinoma: phosphorylated 4E-binding protein-1 expression in endometrial cancer correlates with aggressive tumors and prognosis.
Castellvi J; Garcia A; Ruiz-Marcellan C; Hernández-Losa J; Peg V; Salcedo M; Gil-Moreno A; Ramon y Cajal S
Hum Pathol; 2009 Oct; 40(10):1418-26. PubMed ID: 19428047
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of SPARC protein contrasts with its transcriptional silencing by aberrant hypermethylation of SPARC CpG-rich region in endometrial carcinoma.
Rodríguez-Jiménez FJ; Caldés T; Iniesta P; Vidart JA; Garcia-Asenjo JL; Benito M
Oncol Rep; 2007 Jun; 17(6):1301-7. PubMed ID: 17487382
[TBL] [Abstract][Full Text] [Related]
24. [Recognition of congenital endometrial carcinoma: the importance of family history and investigation of microsatellite instability in the tumour].
Hoogerbrugge N; Overbeek LI; de Hullu J; Kets CM; Hebeda KM; Ligtenberg MJ
Ned Tijdschr Geneeskd; 2007 Jun; 151(26):1441-4. PubMed ID: 17633970
[TBL] [Abstract][Full Text] [Related]
25. Molecular genetics and endometrial cancer.
Oehler MK; Brand A; Wain GV
J Br Menopause Soc; 2003 Mar; 9(1):27-31. PubMed ID: 12804310
[TBL] [Abstract][Full Text] [Related]
26. Predicting favourable prognosis of urothelial carcinoma: gene expression and genome profiling.
van der Kwast TH; Bapat B
Curr Opin Urol; 2009 Sep; 19(5):516-21. PubMed ID: 19553819
[TBL] [Abstract][Full Text] [Related]
27. Use of gene expression profiles to stage concurrent endometrioid tumors of the endometrium and ovary.
Guirguis A; Elishaev E; Oh SH; Tseng GC; Zorn K; DeLoia JA
Gynecol Oncol; 2008 Feb; 108(2):370-6. PubMed ID: 18083218
[TBL] [Abstract][Full Text] [Related]
28. Endometrial carcinoma.
Di Cristofano A; Ellenson LH
Annu Rev Pathol; 2007; 2():57-85. PubMed ID: 18039093
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic utility of phosphatase and tensin homolog, beta-catenin, and p53 for endometrial carcinoma by thin-layer endometrial preparations.
Norimatsu Y; Miyamoto M; Kobayashi TK; Moriya T; Shimizu K; Yanoh K; Tsukayama C; Miyake Y; Ohno E
Cancer; 2008 Jun; 114(3):155-64. PubMed ID: 18431720
[TBL] [Abstract][Full Text] [Related]
30. Mammaglobin expression in the female genital tract: immunohistochemical analysis in benign and neoplastic endocervix and endometrium.
Onuma K; Dabbs DJ; Bhargava R
Int J Gynecol Pathol; 2008 Jul; 27(3):418-25. PubMed ID: 18580321
[TBL] [Abstract][Full Text] [Related]
31. Differential expression of clusterin according to histological type of endometrial carcinoma.
Ahn HJ; Bae J; Lee S; Ko JE; Yoon S; Kim SJ; Sakuragi N
Gynecol Oncol; 2008 Aug; 110(2):222-9. PubMed ID: 18514801
[TBL] [Abstract][Full Text] [Related]
32. From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II.
Young RH
Adv Anat Pathol; 2007 May; 14(3):149-77. PubMed ID: 17452813
[TBL] [Abstract][Full Text] [Related]
33. DNA mismatch repair deficiency in endometrial carcinoma.
Karamurzin Y; Rutgers JK
Int J Gynecol Pathol; 2009 May; 28(3):239-55. PubMed ID: 19620942
[TBL] [Abstract][Full Text] [Related]
34. No difference in the occurrence of mismatch repair defects and APC and CTNNB1 genes mutation in a multi-racial colorectal carcinoma patient cohort.
Tan LP; Ng BK; Balraj P; Lim PK; Peh SC
Pathology; 2007 Apr; 39(2):228-34. PubMed ID: 17454753
[TBL] [Abstract][Full Text] [Related]
35. Somatic FGF9 mutations in colorectal and endometrial carcinomas associated with membranous beta-catenin.
Abdel-Rahman WM; Kalinina J; Shoman S; Eissa S; Ollikainen M; Elomaa O; Eliseenkova AV; Bützow R; Mohammadi M; Peltomäki P
Hum Mutat; 2008 Mar; 29(3):390-7. PubMed ID: 18165946
[TBL] [Abstract][Full Text] [Related]
36. Relationship between tamoxifen use and high risk endometrial cancer histologic types.
Bland AE; Calingaert B; Secord AA; Lee PS; Valea FA; Berchuck A; Soper JT; Havrilesky L
Gynecol Oncol; 2009 Jan; 112(1):150-4. PubMed ID: 18937966
[TBL] [Abstract][Full Text] [Related]
37. Biologic markers in endometrial cancer treatment.
Engelsen IB; Akslen LA; Salvesen HB
APMIS; 2009 Oct; 117(10):693-707. PubMed ID: 19775337
[TBL] [Abstract][Full Text] [Related]
38. Utility of immunohistochemistry in predicting microsatellite instability in endometrial carcinoma.
Modica I; Soslow RA; Black D; Tornos C; Kauff N; Shia J
Am J Surg Pathol; 2007 May; 31(5):744-51. PubMed ID: 17460459
[TBL] [Abstract][Full Text] [Related]
39. FGF2 transcript levels are positively correlated with EGF and IGF-1 in the malignant endometrium.
Soufla G; Sifakis S; Spandidos DA
Cancer Lett; 2008 Feb; 259(2):146-55. PubMed ID: 18006148
[TBL] [Abstract][Full Text] [Related]
40. Models representing type I and type II human endometrial cancers: Ishikawa H and Hec50co cells.
Albitar L; Pickett G; Morgan M; Davies S; Leslie KK
Gynecol Oncol; 2007 Jul; 106(1):52-64. PubMed ID: 17490735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
